KRASG12C IN-16 (Compound SK-17) is a selective, covalent, and orally active KRASG12C inhibitor. It can induce apoptosis and effectively prevent the activation of the MAPK and PI3K/mTOR signaling pathways. Additionally, KRASG12C IN-16 exhibits antitumor activity against pancreatic cancer.
Molekulargewicht:
551.08
Formel:
C28H35ClN8O2
Target-Kategorie:
Kras|||mTOR|||Apoptosis|||p38 MAPK|||Ras|||PI3K
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten